MCID: BLN006
MIFTS: 44

Blind Loop Syndrome

Categories: Gastrointestinal diseases

Aliases & Classifications for Blind Loop Syndrome

MalaCards integrated aliases for Blind Loop Syndrome:

Name: Blind Loop Syndrome 12 45 15 17 74
Bacterial Overgrowth Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10606
ICD9CM 36 579.2
MeSH 45 D001765
NCIt 51 C34431
SNOMED-CT 69 66379009 77225009
ICD10 34 K90.2
UMLS 74 C0005750

Summaries for Blind Loop Syndrome

Disease Ontology : 12 An intestinal disease characterized by a dysbalance of the bacterial flora of the small intestine, causing derangement to the normal physiological processes of digestion and absorption.

MalaCards based summary : Blind Loop Syndrome, also known as bacterial overgrowth syndrome, is related to protein-losing enteropathy and duodenal atresia. An important gene associated with Blind Loop Syndrome is LBP (Lipopolysaccharide Binding Protein), and among its related pathways/superpathways are Selenium Micronutrient Network and Secretion of Hydrochloric Acid in Parietal Cells. The drugs Aspirin and Nitroglycerin have been mentioned in the context of this disorder. Affiliated tissues include small intestine, heart and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Blind loop syndrome (BLS) is a state that occurs when the normal bacterial flora of the small intestine... more...

Related Diseases for Blind Loop Syndrome

Diseases related to Blind Loop Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 protein-losing enteropathy 29.8 ALB SERPINA1
2 duodenal atresia 11.2
3 fungal esophagitis 10.4 ATP12A ATP4A
4 diclofenac allergy 10.4 ATP12A ATP4A
5 neonatal candidiasis 10.4 ATP12A ATP4A
6 photoallergic dermatitis 10.4 ATP12A ATP4A
7 squamous papillomatosis 10.4 ATP12A ATP4A
8 toxic megacolon 10.4 ATP12A ATP4A
9 gastric antral vascular ectasia 10.4 ATP12A ATP4A
10 esophageal candidiasis 10.4 ATP12A ATP4A
11 acute laryngitis 10.4 ATP12A ATP4A
12 duodenitis 10.4 ATP12A ATP4A
13 rumination disorder 10.4 ATP12A ATP4A
14 congenital disorder of deglycosylation 10.4 ATP12A ATP4A
15 bladder calculus 10.4 ATP12A ATP4A
16 ischemic neuropathy 10.4 ATP12A ATP4A
17 bile reflux 10.4 ATP12A ATP4A
18 dyskinesia of esophagus 10.4 ATP12A ATP4A
19 hernia, hiatus 10.4 ATP12A ATP4A
20 hemoglobin lepore-beta-thalassemia syndrome 10.4 HBB HBD
21 anismus 10.4 ATP12A ATP4A
22 hemoglobin d disease 10.4 HBB HBD
23 postsurgical hypothyroidism 10.4 ATP12A ATP4A
24 lymphocytic colitis 10.4 ATP12A ATP4A
25 esophageal atresia/tracheoesophageal fistula 10.4 ATP12A ATP4A
26 clostridium difficile colitis 10.4 ATP12A ATP4A
27 malignant secondary hypertension 10.4 HBB HBD
28 hemoglobin c disease 10.4 HBB HBD
29 diarrhea 1, secretory chloride, congenital 10.4 ATP12A ATP4A
30 esophagitis, eosinophilic, 1 10.4 ATP12A ATP4A
31 hemoglobin e disease 10.4 HBB HBD
32 osgood-schlatter's disease 10.4 HBB HBD
33 microscopic colitis 10.3 ATP12A ATP4A
34 laryngeal tuberculosis 10.3 ATP12A ATP4A
35 fetal hemoglobin quantitative trait locus 1 10.3 HBB HBD
36 eosinophilic gastritis 10.3 ATP12A ATP4A
37 esophagus adenocarcinoma 10.3 ATP12A ATP4A
38 kluver-bucy syndrome 10.3 HBB HBD
39 chronic intestinal vascular insufficiency 10.3 ATP12A ATP4A
40 superior mesenteric artery syndrome 10.3 ATP12A ATP4A
41 lower urinary tract calculus 10.3 ATP12A ATP4A
42 malignant essential hypertension 10.3 HBB HBD
43 myopathy, x-linked, with excessive autophagy 10.3 ATP12A ATP4A
44 pneumatosis cystoides intestinalis 10.3 ATP12A ATP4A
45 drug allergy 10.3 ALB ATP12A
46 lateral medullary syndrome 10.3 ATP12A ATP4A
47 microinvasive gastric cancer 10.3 ATP12A ATP4A
48 pleuropneumonia 10.3 HBB HBD
49 osteopetrosis, autosomal recessive 3 10.2 ATP12A ATP4A
50 aspiration pneumonitis 10.2 ATP12A ATP4A HRH2

Comorbidity relations with Blind Loop Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Blind Loop Syndrome:



Diseases related to Blind Loop Syndrome

Symptoms & Phenotypes for Blind Loop Syndrome

GenomeRNAi Phenotypes related to Blind Loop Syndrome according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.65 LBP
2 Decreased viability GR00381-A-1 9.65 HRH2 LBP MLN
3 Decreased viability GR00381-A-3 9.65 HRH2 LBP MLN
4 Decreased viability GR00402-S-2 9.65 HRH2 LBP MLN
5 Decreased viability with TRAIL GR00240-S-2 8.8 HBD MLN TTR

MGI Mouse Phenotypes related to Blind Loop Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.5 ALB ATP12A ATP4A GHRL HRH2 TNFAIP3
2 homeostasis/metabolism MP:0005376 9.28 ALB ATP12A ATP4A CBLIF GHRL HRH2

Drugs & Therapeutics for Blind Loop Syndrome

Drugs for Blind Loop Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Not Applicable 50-78-2 2244
2
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
3
Pravastatin Approved Phase 4 81093-37-0 54687
4
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Calcium Approved, Nutraceutical Phase 4,Early Phase 1 7440-70-2 271
7 Fibrinolytic Agents Phase 4
8 Antirheumatic Agents Phase 4
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4
10 Analgesics, Non-Narcotic Phase 4
11 Antipyretics Phase 4
12 Peripheral Nervous System Agents Phase 4
13 Cyclooxygenase Inhibitors Phase 4
14 Platelet Aggregation Inhibitors Phase 4
15 Anti-Inflammatory Agents Phase 4,Not Applicable
16 Analgesics Phase 4
17 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
18 Lipid Regulating Agents Phase 4
19 Antimetabolites Phase 4
20 Hormones Phase 4,Early Phase 1
21 Calcium, Dietary Phase 4,Early Phase 1
22 Anticholesteremic Agents Phase 4
23 Hypolipidemic Agents Phase 4
24 Chinese Salvia Phase 4,Not Applicable
25
Silver sulfadiazine Approved, Vet_approved Phase 2 22199-08-2 441244
26
Sulfadiazine Approved, Investigational, Vet_approved Phase 2 68-35-9 5215
27
Ginseng Approved, Investigational, Nutraceutical Phase 2,Not Applicable 50647-08-0
28 Pharmaceutical Solutions Phase 2
29
Neomycin Approved, Vet_approved Not Applicable 1404-04-2 8378
30
Erythromycin Approved, Investigational, Vet_approved Not Applicable 114-07-8 441411 12560
31 Tangerine Approved Not Applicable
32
Ethanol Approved Not Applicable 64-17-5 702
33
Petrolatum Approved, Investigational Not Applicable 8009-03-8
34
Calcitriol Approved, Nutraceutical Early Phase 1 32222-06-3 5280453 134070
35 Liver Extracts Not Applicable
36 Gastrointestinal Agents Not Applicable
37 Erythromycin stearate Not Applicable
38 Anti-Infective Agents Not Applicable
39 Erythromycin Ethylsuccinate Not Applicable
40 Erythromycin Estolate Not Applicable
41 Anti-Bacterial Agents Not Applicable
42 Antibiotics, Antitubercular
43 Astragalus Not Applicable
44 Angelica Not Applicable
45 Dong Quai Not Applicable
46 Vasoconstrictor Agents Early Phase 1
47 Vitamins Early Phase 1
48 Bone Density Conservation Agents Early Phase 1
49 Micronutrients Early Phase 1
50 Nutrients Early Phase 1

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
2 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
3 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
4 Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke Completed NCT01762163 Phase 4 Qizhitongluo Capsule;Naoxintong Capsule;Aspirin Enteric-coated Tablets;placebo
5 Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index Completed NCT01502943 Phase 4 Louxiangdan Tongxin granules;TCM granules placebo;Chixiangshen Tongxin granules;TCM granule placebo plus western basis treatment;Western basis treatment
6 Danhong Injection in the Treatment of Acute Ischemic Stroke Completed NCT01677208 Phase 4 Danhong injection;placebo
7 Clinical Trial Scheme of Xinnaoning Capsule Recruiting NCT03914131 Phase 4 Xinnaoning Capsule
8 The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease Unknown status NCT01615003 Phase 2 Xuesaitong soft capsule;Xuesaitong soft capsule Placebo
9 Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina Unknown status NCT03083119 Phase 2 Xuesaitong soft capsule;Placebo oral capsule
10 Observation on the Curative Effect of Assisted Reproduction by TCM Multi-channel Interventional Therapy Unknown status NCT03078205 Phase 2
11 Uncut Roux-en-Y Gastrojejunostomy for Early Gastric Cancer Patients Unknown status NCT02644148 Phase 2
12 Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy Completed NCT01373476 Phase 2 Qideng Mingmu capsule;Placebo Comparator
13 Observing the Curative Effect of Assisted Reproduction by TCM Multi-channel Interventional Therapy Completed NCT02303665 Phase 2
14 The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome. Recruiting NCT03091634 Phase 2 xue-fu-zhu-yu capsule;xue-fu-zhu-yu capsule simulated agent
15 A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome) Recruiting NCT02875639 Phase 2 Yiqi prescription;Huoxue prescription;Buyang huanwu decoction;QISHEN YIQI DRIPPING PILLS;Placebo 1;Placebo 2
16 Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome Not yet recruiting NCT03942198 Phase 2 Taodan Granules;Taodan Granules Placebo
17 Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome Not yet recruiting NCT03961230 Phase 2 Jueyin granules;Jueyin Granules Placebo
18 Chinese Herbal Medicine for Psoriasis Vulgaris: a Real World Study Not yet recruiting NCT03942185 Phase 2 Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy;Oral Chinese Herbal Medicine according with syndrome differentiation therapy;Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy
19 Clinical Evaluation and Generalized Application of "Qing-Hua-Bu" Three Dynamic Sequential Therapy of Diabetic Ulcer Not yet recruiting NCT03574935 Phase 2 External Chinese medicine;External Western medicine
20 Screening Protein Markers in Patients With Rheumatoid Arthritis and Hot-dampness and Blood Stasis Syndrome Unknown status NCT02408094
21 Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome Unknown status NCT02967718
22 Clinical Study On The Relation Among Prescription, Syndrome and Disease of Turbid Phlegm and Blood Stasis for Coronary Heart Disease Unknown status NCT02526381 Not Applicable Danlou Tablets;Tongmai Yangxin Pills
23 Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy Unknown status NCT01097811 Not Applicable Erythromycin;Neomycin
24 Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing Completed NCT01324895
25 Dynamic Combination Therapy on Chinese Herbal Granules to Improve the Symptoms in Convalescent Phase of Ischemic Stroke Completed NCT01780480 Not Applicable Dynamic Chinese herbal granule formula;Placebo
26 Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS) Completed NCT00858130 Not Applicable
27 Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations Completed NCT01636154 Not Applicable Ixeris of sonchifolia Hance;Panax notoginseng saponins;Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
28 Small Intestinal Bacterial Overgrowth Obese Recruiting NCT02819037 Not Applicable
29 Uncut Roux-en-Y vs Roux-en-Y Recruiting NCT03349398 Not Applicable
30 Yiqi Huoxue Demolition and Recipes on Recovery Stage of Cerebral Infarction Recruiting NCT02846207 Not Applicable Yiqi huoxue;Yiqi group;Huoxue group;placebo
31 Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction Recruiting NCT02544087 Not Applicable Ixeris of sonchifolia Hance;Panax notoginseng saponins;Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
32 Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide Recruiting NCT03186625 Not Applicable Compound Panax Notoginseng Granule;Placebo Granule
33 Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome Not yet recruiting NCT03953885 Not Applicable
34 Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules Not yet recruiting NCT03563235 Early Phase 1 Xulin Jiangu granules;Calcitriol capsules
35 Moving Cupping for Plaque Psoriasis: a Randomized Controlled Trial Not yet recruiting NCT03952676 Not Applicable
36 Clinical Trial of PSORI-CM01(YXBCM01) Granule to Treat Stable Plaque Psoriasis Terminated NCT02153840 Not Applicable PSORI-CM01(YXBCM01) granule;placebo

Search NIH Clinical Center for Blind Loop Syndrome

Cochrane evidence based reviews: blind loop syndrome

Genetic Tests for Blind Loop Syndrome

Anatomical Context for Blind Loop Syndrome

MalaCards organs/tissues related to Blind Loop Syndrome:

42
Small Intestine, Heart, Liver, Testes, Skin, Kidney, Bone

Publications for Blind Loop Syndrome

Articles related to Blind Loop Syndrome:

(show top 50) (show all 104)
# Title Authors Year
1
Small Intestinal Bacterial Overgrowth Syndrome Prevalence in Romanian Patients with Inflammatory Bowel Disease. ( 30568826 )
2016
2
The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. ( 26374094 )
2015
3
Small intestinal bacterial overgrowth syndrome in children. ( 25960812 )
2015
4
A Case of Blind Loop Syndrome Caused by Infection with Giardia duodenalis Diagnosed with Double Balloon Enteroscopy. ( 25408630 )
2014
5
Comparison of two shampoos as sole treatment for canine bacterial overgrowth syndrome. ( 22678617 )
2012
6
Migrating motor complex changes after side-to-side ileal bypass in mouse ileum ex-vivo: mechanism underlying the blind loop syndrome? ( 22066044 )
2011
7
Small intestinal bacterial overgrowth syndrome. ( 20572300 )
2010
8
Bacterial overgrowth syndrome in myotonic muscular dystrophy is potentially treatable. ( 21104859 )
2010
9
Reversible acute reactive arthritis secondary to iatrogenic blind loop syndrome. ( 17925936 )
2007
10
Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy. Do small bowel bacterial overgrowth syndrome and occult zinc ingestion tip the balance? ( 17415508 )
2007
11
Gut flora in health and small intestinal bacterial overgrowth syndrome. ( 18050837 )
2007
12
Gut flora in health and small intestinal bacterial overgrowth syndrome. ( 18384008 )
2007
13
Prospective study of bacterial overgrowth syndrome in eight dogs. ( 16581994 )
2006
14
Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. ( 15813834 )
2005
15
Leiomyosarcoma of the small intestine presenting with bacterial overgrowth syndrome. ( 11743261 )
2002
16
Enteric bacterial flora and bacterial overgrowth syndrome. ( 12462706 )
2002
17
Blind loop syndrome after biliopancreatic diversion: a diagnostic challenge. ( 11594112 )
2001
18
Small Intestinal Bacterial Overgrowth Syndrome. ( 11177677 )
2001
19
Rapid enantiomeric differentiation of urinary metabolites in a patient with bacterial overgrowth syndrome. ( 10973888 )
2000
20
Blind loop syndrome. Diagnosis by In-111-labeled leukocyte scintigraphy. ( 10439196 )
1999
21
Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. ( 10235214 )
1999
22
Blind loop syndrome: an unusual cause of panniculitis. ( 9366844 )
1997
23
The ursodeoxycholic acid-p-aminobenzoic acid deconjugation test, a new tool for the diagnosis of bacterial overgrowth syndrome. ( 9262976 )
1997
24
Blind loop syndrome: multiple ileal ulcers following side-to-side anastomosis. ( 8165008 )
1993
25
The blind loop syndrome in children. ( 2401946 )
1990
26
The deconjugation ability of bacteria isolated from the jejunal fluids in the blind loop syndrome with high 14CO2 excretion--using the breath analysis technique and thin-layer chromatography. ( 2513463 )
1989
27
Percutaneous duodenostomy in blind loop syndrome. ( 2451880 )
1988
28
Impaired intestinal sodium and chloride transport in the blind loop syndrome of the rat. ( 2434383 )
1987
29
Ischemic jejunal stenosis and blind loop syndrome after blunt abdominal trauma. ( 3559122 )
1987
30
Adaptation of the jejunal mucosa in the experimental blind loop syndrome: changes in paracellular conductance and tight junction structure. ( 3692303 )
1987
31
Small bowel bacterial overgrowth syndrome. ( 3311488 )
1987
32
Postgastrectomy blind loop syndrome and the arthritis-dermatitis syndrome. ( 3970735 )
1985
33
Blind loop syndrome, vitamin E malabsorption, and spinocerebellar degeneration. ( 3974892 )
1985
34
Choledochoduodenostomy and the blind loop syndrome. ( 4041721 )
1985
35
Short-chain fatty acids in the small-bowel bacterial overgrowth syndrome. ( 4023615 )
1985
36
Altered motility and duration of bacterial overgrowth in experimental blind loop syndrome. ( 6376005 )
1984
37
Breath hydrogen test in infants and children with blind loop syndrome. ( 6737180 )
1984
38
Blind loop syndrome and small bowel bacterial contamination. ( 6347463 )
1983
39
Altered myoelectric activity in the experimental blind loop syndrome. ( 6350361 )
1983
40
Small bowel bacterial overgrowth syndrome. ( 6353559 )
1983
41
Blind loop syndrome following iatrogenic intestinal bypass in a child. ( 7141516 )
1982
42
Glycoprotein degradation in the blind loop syndrome: identification of glycosidases in jejunal contents. ( 6257760 )
1981
43
Gut damage in human blind-loop syndrome. ( 7239120 )
1981
44
Importance of anaerobic bacteria in the cobalamin malabsorption of the experimental rat blind loop syndrome. ( 7450422 )
1981
45
Protein-losing enteropathy in the human and experimental rat blind-loop syndrome. ( 7450442 )
1981
46
Small intestinal bacterial overgrowth syndrome. ( 6781975 )
1981
47
Sensitivity of bile acid breath test in the diagnosis of bacterial overgrowth in the small intestine with and without the stagnant (blind) loop syndrome. ( 428288 )
1979
48
Osteomalacia complicating a blind loop syndrome from congenital megaesophagus-megaduodenum. ( 439112 )
1979
49
Protein digestion and absorption in the blind loop syndrome. ( 510093 )
1979
50
Xylose catabolism in the experimental rat blind loop syndrome: studies, including use of a newly developed d-[14C]xylose breath test. ( 631506 )
1978

Variations for Blind Loop Syndrome

Expression for Blind Loop Syndrome

Search GEO for disease gene expression data for Blind Loop Syndrome.

Pathways for Blind Loop Syndrome

Pathways related to Blind Loop Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.47 ALB CBLIF HBB
2 9.32 ATP4A HRH2

GO Terms for Blind Loop Syndrome

Cellular components related to Blind Loop Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ALB CBLIF GHRL HBB LBP MLN
2 blood microparticle GO:0072562 9.5 ALB HBB HBD
3 hemoglobin complex GO:0005833 9.26 HBB HBD
4 extracellular space GO:0005615 9.23 ALB ATP4A CBLIF GHRL HBB LBP
5 haptoglobin-hemoglobin complex GO:0031838 9.16 HBB HBD

Biological processes related to Blind Loop Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.69 ALB SERPINA1 TTR
2 blood coagulation GO:0007596 9.65 HBB HBD SERPINA1
3 acute-phase response GO:0006953 9.49 LBP SERPINA1
4 ATP hydrolysis coupled proton transport GO:0015991 9.46 ATP12A ATP4A
5 hydrogen peroxide catabolic process GO:0042744 9.43 HBB HBD
6 cellular sodium ion homeostasis GO:0006883 9.4 ATP12A ATP4A
7 oxygen transport GO:0015671 9.37 HBB HBD
8 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.32 ATP12A ATP4A
9 cellular potassium ion homeostasis GO:0030007 9.26 ATP12A ATP4A
10 sodium ion export across plasma membrane GO:0036376 9.16 ATP12A ATP4A
11 negative regulation of interleukin-1 beta production GO:0032691 8.96 GHRL TNFAIP3
12 cellular oxidant detoxification GO:0098869 8.8 ALB HBB HBD

Molecular functions related to Blind Loop Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.58 GHRL MLN TTR
2 peroxidase activity GO:0004601 9.46 HBB HBD
3 oxygen carrier activity GO:0005344 9.43 HBB HBD
4 sodium:potassium-exchanging ATPase activity GO:0005391 9.37 ATP12A ATP4A
5 organic acid binding GO:0043177 9.32 HBB HBD
6 haptoglobin binding GO:0031720 9.26 HBB HBD
7 hemoglobin alpha binding GO:0031721 9.16 HBB HBD
8 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP12A ATP4A
9 oxygen binding GO:0019825 8.8 ALB HBB HBD

Sources for Blind Loop Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....